Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study-Reference-Cited by-同舟云学术

Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study

Published:2022-12-05 Issue:6 Volume:200 Page:802-811
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kuwana Masataka¹^ORCID,Ito Tomoki²^ORCID,Kowata Shugo³^ORCID,Hatta Yoshihiro⁴,Fujimaki Katsumichi⁵^ORCID,Naito Kensuke⁶,Kurahashi Shingo⁷,Kagoo Toshiya⁸^ORCID,Tanimoto Kazuki⁹,Saotome So¹⁰,Tomiyama Yoshiaki¹¹^ORCID,Koike Michiaki,Nakajima Yuki,Harada Hiroshi,Hangaishi Akira,Yokoyama Kenji,Cho Ryuko,Kyoda Katsunori,Kakinoki Yasutaka,Yoshida Masahiro,Shimizu Seiichi,Kashiwagi Hirokazu,Kirito Keita,Yokota Akira,Kikuchi Takahide,Harada Naoki,Imamura Yutaka,Yano Tomofumi,Kosugi Hiroshi,Ogawa Ryosuke,Okamura Atsuo,Yamaguchi Masaki,Yoshimitsu Makoto,Motomura Sayuri,Ito Toshiro,Yamanouchi Jun,Katsutani Shinya,Hiramatsu Yasushi,Asagoe Kohsuke,

Affiliation:

1. Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine Tokyo Japan

2. First Department of Internal Medicine Kansai Medical University Osaka Japan

3. Division of Hematology and Oncology Department of Internal Medicine, Iwate Medical University Iwate Japan

4. Department of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan

5. Department of Hematology Fujisawa City Hospital Kanagawa Japan

6. Department of Hematology Hamamatsu Medical Center Shizuoka Japan

7. Department of Hematology and Oncology Toyohashi Municipal Hospital Aichi Japan

8. Division of Hematology, Department of Internal Medicine National Hospital Organization Tokyo Medical Center Tokyo Japan

9. Hematology and Oncology Division Japanese Red Cross Fukuoka Hospital Fukuoka Japan

10. Kissei Pharmaceutical Co., Ltd. Tokyo Japan

11. Department of Blood Transfusion Osaka University Hospital Osaka Japan

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18582

Reference31 articles.

1. Immune Thrombocytopenic Purpura

2. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

3. The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts

4. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan

5. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database;Expert Opinion on Drug Safety;2024-08

2. Fostamatinib for immune thrombocytopenic purpura in adult patients: A systematic review and meta‐analysis;eJHaem;2024-06-21

3. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials;Annals of Hematology;2024-06-10

4. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study;British Journal of Haematology;2024-04-03

5. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management;Expert Review of Hematology;2024-02-19